Lymphatic and blood vessel density in the follicular patterned lesions of thyroid

Modern Pathology

Volumn 18, Issue 11, 2005, Pages 1424-1431

  Giorgadze, Tamar A ^a   Baloch, Zubair W ^b   Pasha, Teresa ^b   Zhang, Paul J ^b   LiVolsi, Virginia A ^b  

^a East Tennessee State University   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Differential diagnosis; Follicular patterned lesions of thyroid; General vessel density; Immunohistochemistry; Lymphatic vessel density

Indexed keywords

ARTICLE; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EVALUATION; FOLLICULAR CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; LYMPHANGIOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; CARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; NEOVASCULARIZATION, PATHOLOGIC; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 27144535902     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800452     Document Type: Article

References (24)

1. Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004;28:1336-1340.
2. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000;166:475-480.
3. Turner HE, Harris AL, Melmed S, et al. Angiogenesis in endocrine tumors. Endocr Rev 2003;24:600-632.
4. Fellmer PT, Sato K, Tanaka R, et al. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 1999;126:1056-1061.
5. Hung CJ, Ginzinger DG, Zarnegar R, et al. Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J Clin Endocrinol Metab 2003;88:3694-3699.
6. Herrmann G, Schumm-Draeger PM, Muller C, et al. T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. J Cancer Res Clin Oncol 1994;120:651-656.
7. Fontanini G, Vignati S, Pacini F, et al. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol 1996;9:636-641.
8. Segal K, Shpitzer T, Feinmesser M, et al. Angiogenesis in follicular tumors of the thyroid. J Surg Oncol 1996;63:95-98.
9. Ishiwata T, Iino Y, Takei H, et al. Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep 1998;5:1343-1348.
10. Goldenberg JD, Portugal LG, Wenig BL, et al. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density. Head Neck 1998;20:152-158.
11. Dhar DK, Kubota H, Kotoh T, et al. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am J Surg 1998;176:442-447.
12. Akslen LA, LiVolsi VA. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol 2000;31:439-442.
13. Tanaka K, Sonoo H, Kurebayashi J, et al. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. Clin Cancer Res 2002;8:1125-1131.
14. Hall FT, Freeman JL, Asa SL, et al. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2003;129:716-719.
15. Fox SB. Tumour angiogenesis and prognosis. Histopathology 1997;30:294-301.
16. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001;7:462-468.
17. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155:1967-1976.
18. Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997;82:3741-3747.
19. Iitaka M, Miura S, Yamanaka K, et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1998;83:3908-3912.
20. Klein M, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999;161:41-49.
21. Kilicarslan AB, Ogus M, Arici C, et al. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 2003;111:439-443.
22. Lennard CM, Patel A, Wilson J, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001;129:552-558.
23. Giorgadze TA, Zhang PJ, Pasha T, et al. Lymphatic vessel density is significantly increased in melanoma. J Cutan Pathol 2004;31:672-677.
24. Dumoff KL, Chu C, Xu X, et al. Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol 2005;18:97-104.